Compare Ecopetrol SA (EC) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs Globus Medical Inc. Class A Common Stock — how do they compare? Ecopetrol SA trades at $18 (market cap $33.52B), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: Ecopetrol SA is far larger — about 3.3× Globus Medical Inc. Class A Common Stock's market cap, and Ecopetrol SA pays a 3.71% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecopetrol SA for 84 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| EC | GMED | |
|---|---|---|
Market Cap | $33.52B | $10.25B |
Volume | 1,602,222 | 1,108,124 |
Sector | Energy | Health |
52-Week High | $18.26 | $96.82 |
52-Week Low | $8.61 | $58.33 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $62.13B | $9.76B |
Dividend Yield | 3.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $17.90, up 3.89% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. Revenue has declined from $159.61T in 2022 to $119.69T in 2025, with net income margin falling to 8.76%. Recent management changes and board appointments signal corporate transformation efforts, while analyst consensus is cautious with a 'Reduce' rating and $16.85 price target.
The stock faces headwinds from declining profitability and revenue, offset by low valuation multiples (P/E 8.27, EV/EBITDA 4). Risks include political influence, corruption probes, and oil price volatility. Upside depends on execution under new leadership and stabilization of financials, but current sentiment remains neutral to bearish amid operational challenges.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →
